Imjudo

Active Ingredient(s): Tremelimumab-actl
FDA Approved: * October 21, 2022
Pharm Company: * ASTRAZENECA AB
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Imjudo 25 mg/1.25ml Intravenous Injection, Solution
NDC: 0310-4505
Labeler:
Astrazeneca Pharmaceuticals Lp
Imjudo 300 mg/15ml Intravenous Injection, Solution
NDC: 0310-4535
Labeler:
Astrazeneca Pharmaceuticals Lp